3:38 PM
 | 
Nov 22, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ABTL0812: Ph II started

Ability began an open-label, Spanish and French Phase II trial to evaluate 1,500-3,900 mg oral ABTL0812 as first-line therapy in combination with paclitaxel and carboplatin in 80 patients with...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >